This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.
Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug
by Zacks Equity Research
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Merck (MRK) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.
Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval
by Zacks Equity Research
Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin disease (CAD) in Europe.
Pharma Stock Roundup: RHHBY's Alzheimer's Study Failure, EU Nod for SNY's Enjaymo
by Kinjel Shah
Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.
Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.
Novartis (NVS) Reportedly Looking to Sell Its Business Units
by Zacks Equity Research
Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023?
by Zacks Equity Research
Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use
by Zacks Equity Research
The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod
by Zacks Equity Research
AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.
The Zacks Analyst Blog Highlights Archer Daniels Midland, Charles River Associates, Murphy USA, Merck and New Fortress Energy
by Zacks Equity Research
Archer Daniels Midland, Charles River Associates, Murphy USA, Merck and New Fortress Energy are included in this Analyst Blog.
Here is Why Growth Investors Should Buy Merck (MRK) Now
by Zacks Equity Research
Merck (MRK) possesses solid growth attributes, which could help it handily outperform the market.
Are Investors Undervaluing Innoviva (INVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Cheers Soft Inflation Data: 5 Growth Picks
by Tirthankar Chakraborty
Invest in growth stocks like Murphy USA (MUSA), Merck (MRK) & New Fortress Energy (NFE), to name a few, as Wall Street rises on signs of cooling inflation.
AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up
by Zacks Equity Research
AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.
Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.
Merck & Co., Inc. (MRK) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook
by Zacks Equity Research
Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.
Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
The Zacks Analyst Blog Highlights Merck, ConocoPhillips, Adobe, Intercontinental Exchange and Monster Beverage
by Zacks Equity Research
Merck, ConocoPhillips, Adobe, Intercontinental Exchange and Monster Beverage are included in this Analyst Blog.
Top Research Reports for Merck, ConocoPhillips & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ConocoPhillips (COP) and Adobe Inc. (ADBE).